Features of patients with uveitis associated with juvenile idiopathic arthritis required eye surgery

Table 1 Descriptive statistic characteristics of the studied population

Parameter	Result
Sex, females	44 (64.7)
HLA-B27-positivity	7 (22.6)
ANA positivity	41 (61.2)
Type of arthritis
Oligoarthritis	43 (63.2)
ERA	11 (16.2)
Psoriatic arthritis	2 (2.9)
Undifferentiated arthritis	12 (17.7)
Age at onset of uveitis, years	7.0 (4.4-9.6)
Patients who underwent eye surgery	17 (25.0)
Time to eye surgery, years	2.5 (1.1-6.6)
MTX therapy	55.0 (80.9)
Time to MTX initiation, years	0.33 (0.08-1.48)
Remission achieved on MTX	39 (70.9)
Time to remission on MTX, years	0.33 (0.25-0.58)
Patients who flared on MTX	25 (46.3)
Time to first flare on MTX, years	0.6 (0.3-1.1)
bDMARDs received	44 (64.7)
Time to initiation of bDMARD therapy, years	1.62 (0.65-3.67)
Remission achieved on bDMARD therapy	35 (77.8)
Time to remission, years	0.2 (0.1-0.4)
Flare on bDMARD therapy	18 (52.9)
Time to first flare on bDMARD therapy, years	1.6 (0.8-2.5)
Received intraocular corticosteroids	32 (47.1)
Time to intraocular corticosteroid injection, years	0.08 (0.00-1.80)
Time between MTX and bDMARD therapy, years	1.0 (0.4-1.5)

Data are presented as n (%). HLA-B27: Human leukocyte antigen-B27; ANA: Antinuclear antibody; ERA: Enthesitis-related arthritis; MTX: Methotrexate; bDMARDs: Biological disease-modifying antirheumatic drugs.